Serum progranulin levels are elevated in dermatomyositis patients with acute interstitial lung disease, predicting prognosis

Arthritis Research and Therapy

Volumn 17, Issue 1, 2015, Pages

  Tanaka, Atsushi ^a   Tsukamoto, Hiroshi ^a   Mitoma, Hiroki ^a   Kiyohara, Chikako ^a   Ueda, Naoyasu ^a   Ayano, Masahiro ^a   Ohta, Shun ichiro ^a   Kimoto, Yasutaka ^b   Akahoshi, Mitsuteru ^a   Arinobu, Yojiro ^a   Niiro, Hiroaki ^a   Tada, Yoshifumi ^c   Horiuchi, Takahiko ^b   Akashi, Koichi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY BEPPU HOSPITAL   (Japan)

^c SAGA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FERRITIN; HEMOGLOBIN; IMMUNOSUPPRESSIVE AGENT; KREBS VON DEN LUNGEN 6; LACTATE DEHYDROGENASE; METHOTREXATE; MIZORIBINE; PREDNISOLONE; PROGRANULIN; TACROLIMUS; UNCLASSIFIED DRUG; GRN PROTEIN, HUMAN; SIGNAL PEPTIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; CROSS-SECTIONAL STUDY; DERMATOMYOSITIS; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FERRITIN BLOOD LEVEL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; POLYMYOSITIS; PREDICTION; PROGNOSIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SURVIVAL RATE; BLOOD; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; CROSS-SECTIONAL STUDIES; DERMATOMYOSITIS; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED;

EID: 84928776633     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-015-0547-z     Document Type: Article

References (47)

1. Callen J. Dermatomyositis Lancet. 2000;355:53-7.
2. Ito M, Kaise S, Suzuki S, Kazuta Y, Sato Y, Miyata M, et al. Clinico-laboratory characteristics of patients with dermatomyositis accompanied by rapidly progressive interstitial lung disease. Clin Rheumatol. 1999;18:462-7.
3. Schnabel A, Reuter M, Biederer J, Richter C, Gross W. Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthritis Rheum. 2003;32:273-84.
4. Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005;52:1571-6.
5. Ye S, Chen X, Lu X, Wu MF, Deng Y, Huang WQ, et al. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study. Clin Rheumatol. 2007;26:1647-54.
6. Euwer RL, Sontheimer RD. Amyopathic dermatomyositis: a review. J Invest Dermatol. 1993;100:124S-7.
7. Kameda H, Nagasawa H, Ogawa H, Sekiguchi N, Takei H, Tokuhira M, et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol. 2005;32:1719-26.
8. Saketkoo LA, Ascherman DP, Cottin V, Christopher-Stine L, DanoffSK, Oddis CV. Interstitial lung disease in idiopathic inflammatory myopathy. Curr Rheumatol Rev. 2010;6:108-19.
9. Connors GR, Christopher-Stine L, Oddis CV, DanoffSK. Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? Chest. 2010;138:1464-74.
10. Labirua A, Lundberg IE. Interstitial lung disease and idiopathic inflammatory myopathies: progress and pitfalls. Curr Opin Rheumatol. 2010;22:633-8.
11. Nakashima R, Imura Y, Kobayashi S, Yukawa N, Yoshifuji H, Nojima T, et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford). 2010;49:433-40.
12. Gono T, Kawaguchi Y, Hara M, Masuda I, Katsumata Y, Shinozaki M, et al. Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford). 2010;49:1354-60.
13. Gono T, Kawaguchi Y, Satoh H, Kuwana M, Katsumata Y, Takagi K, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford). 2010;49:1713-9.
14. Gono T, Kawaguchi Y, Ozeki E, Ota Y, Satoh T, Kuwana M, et al. Serum ferritin correlates with activity of anti-MDA5 antibody-associated acute interstitial lung disease as a complication of dermatomyositis. Mod Rheumatol. 2011;21:223-7.
15. Bandoh S, Fujita J, Ohtsuki Y, Ueda Y, Hojo S, Tokuda M, et al. Sequential changes of KL-6 in sera of patients with interstitial pneumonia associated with polymyositis/dermatomyositis. Ann Rheum Dis. 2000;59:257-62.
16. Kubo M, Ihn H, Yamane K, Kikuchi K, Yazawa N, Soma Y, et al. Serum KL-6 in adult patients with polymyositis and dermatomyositis. Rheumatology (Oxford). 2000;39:632-6.
17. Satoh H, Kurishima K, Ishikawa H, Ohtsuka M. Increased levels of KL-6 and subsequent mortality in patients with interstitial lung disease. J Intern Med. 2006;260:429-34.
18. Kumánovics G, Minier T, Radics J, Pálinkás L, Berki T, Czirják L. Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato/polymyositis. Clin Exp Rheumatol. 2008;26:414-20.
19. Fathi M, Barbasso Helmers S, Lundberg IE. KL-6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis. J Intern Med. 2012;271:589-97.
20. He Z, Bateman A. Progranulin (granulin-epithelin precursor, PC-cell-derived growth factor, acrogranin) mediates tissue repair and tumorigenesis. J Mol Med. 2003;81:600-12.
21. Bateman A, Bennett HP. The granulin gene family: from cancer to dementia. Bioessays. 2009;31:1245-54.
22. Daniel R, He Z, Carmichael KP, Halper J, Bateman A. Cellular localization of gene expression for progranulin. J Histochem Cytochem. 2000;48:999-1009.
23. He Z, Ong CH, Halper J, Bateman A. Progranulin is a mediator of the wound response. Nat Med. 2003;9:225-9.
24. Van Damme P, Van Hoecke A, Lambrechts D, Vanacker P, Bogaert E, van Swieten J, et al. Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. J Cell Biol. 2008;181:37-41.
25. Yin F, Banerjee R, Thomas B, Zhou P, Qian L, Jia T, et al. Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. J Exp Med. 2010;207:117-28.
26. Kessenbrock K, Fröhlich L, Sixt M, Lämmermann T, Pfister H, Bateman A, et al. Proteinase 3 and neutrophil elastase enhance inflammation in mice by inactivating antiinflammatory progranulin. J Clin Invest. 2008;118:2438-47.
27. Park B, Buti L, Lee S, Matsuwaki T, Spooner E, Brinkmann MM, et al. Granulin is a soluble cofactor for Toll-like receptor 9 signaling. Immunity. 2011;34:505-13.
28. Tanaka A, Tsukamoto H, Mitoma H, Kiyohara C, Ueda N, Ayano M, et al. Serum progranulin levels are elevated in patients with systemic lupus erythematosus, reflecting disease activity. Arthritis Res Ther. 2012;14:R244.
29. Kim GT, Cho ML, Park YE, Yoo WH, Kim JH, Oh HJ, et al. Expression of TLR2, TLR4, and TLR9 in dermatomyositis and polymyositis. Clin Rheumatol. 2010;29:273-9.
30. Brunn A, Zornbach K, Hans VH, Haypt WF, Deckert M. Toll-like receptors promote inflammation in idiopathic inflammatory myopathies. J Neuropathol Exp Neurol. 2012;71:855-67.
31. Sun WC, Sun YC, Lin H, Yan B, Shi GX. Dysregulation of the type I interferon system in adult-onset clinically amyopathic dermatomyositis has a potential contribution to the development of interstitial lung disease. Br J Dermatol. 2012;167:1236-44.
32. Bilgic H, Ytterberg S, Amin S, McNallan KT, Wilson JC, Koeuth T, et al. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum. 2009;60:3436-46.33. Nara M, Komatsuda A, Omokawa A, Togashi M, Okuyama S, Sawada K, et al. Serum interleukin 6 levels as a useful prognostic predictor of clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease. Mod Rheumatol. 2014;24:633-6.
33. Haddad F, Zaldivar F, Cooper DM, Adams GR. IL-6-induced skeletal muscle atrophy. J Appl Physiol. 2005;98:911-7.
34. Okiyama N, Sugihara T, Iwakura Y, Yokozeki H, Miyasaka N, Kohsaka H. Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A. Arthritis Rheum. 2009;60:2505-12.
35. Bohan A, Peter J. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292:344-7.
36. Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis siné myositis) as a distinctive subset within the idiopathic inflammatory dermatomyositis spectrum of clinical illness? J Am Acad Dermatol. 2002;46:626-36. A published erratum appears in J Am Acad Dermatol. 2002;46:699.
37. American Thoracic Society, European Respiratory Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International Consensus Statement. Am J Respir Crit Care Med. 2000;161:646-64.
38. Oryoji K, Himeji D, Nagafuji K, Horiuchi T, Tsukamoto H, Nondo H, et al. Successful treatment of rapidly progressive interstitial pneumonia with autologous peripheral blood stem cell transplantation in a patient with dermatomyositis. Clin Rheumatol. 2005;24:637-40.
39. Gono T, Miyake K, Kawaguchi Y, Kaneko H, Shinozaki M, Yamanaka H. Hyperferritinemia and macrophage activation in a patient with interstitial lung disease with clinically amyopathic DM. Rheumatology (Oxford). 2012;51:1336-8.
40. Kessenbrock K, Dau T, Jenne DE. Tailor-made inflammation: how neutrophil serine proteases modulate the inflammatory response. J Mol Med. 2011;89:23-8.
41. Tang W, Lu Y, Tian QY, Zhang Y, Guo FJ, Liu GY, et al. The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science. 2011;332:478-84.
42. Ihn H, Asano Y, Kubo M, Yamane K, Jinnin M, Yazawa N, et al. Clinical significance of serum surfactant protein D (SP-D) in patients with polymyositis/dermatomyositis: correlation with interstitial lung disease. Rheumatology (Oxford). 2002;41:1268-72.
43. Nakajima H, Harigai M, Hara M, Hakoda M, Tokuda H, Sakai F, et al. KL-6 as a novel serum marker for interstitial pneumonia associated with collagen disease. J Rheumatol. 2000;27:1164-70.
44. Matsubara T, Mita A, Minami K, Hosooka T, Kitazawa S, Takahashi K, et al. PGRN is a key adipokine mediating high fat diet-induced insulin resistance and obesity through IL-6 in adipose tissue. Cell Metab. 2012;15:38-50.
45. Jacob N, Stohl W. Cytokine disturbances in systemic lupus erythematosus. Arthritis Res Ther. 2011;13:228.
46. Papadimitraki ED, Choulaki C, Koutala E, Bertsias G, Tsatsanis C, Gergianaki I, et al. Expansion of Toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. Arthritis Rheum. 2006;54:3601-11.
47. Jian J, Konopka J, Liu C. Insights into the role of progranulin in immunity, infection, and inflammation. J Leukoc Biol. 2013;93:199-208.